---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-25-000085"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T05:35:43.718666+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Xeris Q1 revenue up 48% to $60.1M; Recorlev surges 141%; tightens FY guidance to $260-275M

## Summary
- Total revenue $60.1M (+48% YoY); net loss $9.2M ($0.06 loss per share) vs prior year loss.
- Recorlev revenue $25.5M (+141%); Gvoke $20.8M (+26%); Keveyis $11.4M (-13%).
- Adjusted EBITDA positive $4.4M, an improvement of $8.4M vs Q1 2024.
- FY 2025 total revenue guidance tightened to $260M-$275M from $255M-$275M.
- Announces Analyst & Investor Day on June 3, 2025 in NYC to discuss Recorlev and XP-8121.

## SEC filing metadata
- accession: 0001867096-25-000085
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709625000085/0001867096-25-000085-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709625000085/xers-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-25-000085
- JSON: https://secwatch.observer/filing/0001867096-25-000085.json
- Plain text: https://secwatch.observer/filing/0001867096-25-000085.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.